SCHEMBL6380450

SCHEMBL6380450

O=C(O)C(=Cc1ccc(O)c(O)c1)C(=Cc1ccc(O)c(O)c1)C(=O)O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 7/20 0.61
JUN P05412 1/20 0.55
KDM4E B2RXH2 6/20 0.55
HSD17B10 Q99714 5/20 0.55
MEN1 O00255 4/20 0.55
ALDH1A1 P00352 4/20 0.55
MAPT P10636 4/20 0.55
HPGD P15428 4/20 0.55
KMT2A Q03164 4/20 0.55
LMNA P02545 3/20 0.55
CYP3A4 P08684 3/20 0.55
MAPK1 P28482 3/20 0.55
PMP22 Q01453 3/20 0.55
TDP1 Q9NUW8 3/20 0.55
HIF1A Q16665 3/20 0.55
POLB P06746 3/20 0.55
NFKB1 P19838 2/20 0.55
CYP2C9 P11712 2/20 0.55
TSHR P16473 2/20 0.55
APEX1 P27695 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15082748 0.96 EGFR (0.61) EGFRJUNKDM4EHSD17B10MEN1
SCHEMBL2879088 0.89 MAPT (0.57) EGFRJUNKDM4EHSD17B10MEN1
SCHEMBL31452785 0.89 MAPT (0.57) EGFRJUNKDM4EHSD17B10MEN1
SCHEMBL7585198 0.84 HSD17B10 (0.62) EGFRKDM4EHSD17B10MEN1ALDH1A1
SCHEMBL2464283 0.83 EGFR (0.61) EGFRJUNKDM4EHSD17B10MEN1
SCHEMBL22543058 0.83 EGFR (0.61) EGFRJUNKDM4EHSD17B10MEN1
SCHEMBL9315356 0.82 MAPT (0.67) EGFRJUNKDM4EHSD17B10MEN1
SCHEMBL28152629 0.81 EGFR (0.63) EGFRJUNKDM4EHSD17B10MEN1
SCHEMBL10554055 0.80 EGFR (0.57) EGFRJUNKDM4EHSD17B10MEN1
SCHEMBL1462507 0.80 EGFR (0.57) EGFRJUNKDM4EHSD17B10MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050049242-A1 Novel HIV integrase inhibitors and HIV therapy based on drug combinations including integrase inhibitors NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2005-03-03 US disclosed
EP-1063888-A1 NOVEL HIV INTEGRASE INHIBITORS AND HIV THERAPY BASED ON DRUG COMBINATIONS INCLUDING INTEGRASE INHIBITORS The Regents of the University of California (US) 2001-01-03 EP disclosed
WO-1999048371-A1 NOVEL HIV INTEGRASE INHIBITORS AND HIV THERAPY BASED ON DRUG COMBINATIONS INCLUDING INTEGRASE INHIBITORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1999-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050049242-A1 Novel HIV integrase inhibitors and HIV therapy based on drug combinations including integrase inhibitors DDO, DNTT, DSTYK EGFR 2913/4885JUN 2338/4885KDM4E 255/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.